Catalog Number : 500-P11
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIGF-I. Anti-Human IGF-I specific antibody was purified by affinity chromatography employing immobilized hIGF-I matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human IGF-I (BioGems Catalog #100-11)
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.25 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Optimal results for these conditions were achieved without antigen retrieval. Optimal concentrations and conditions may vary.
To yield one-half maximal inhibition [ND50] of the biological activity of hIGF-I (5.0 ng/ml), a concentration of 0.67 - 1.0 µg/ml of this antibody is required.
To detect hIGF-I by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human IGF-I (60-186BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIGF-I.
To detect hIGF-I by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIGF-I is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.